Connecting the dots: Market access in the biotech industry with Ning Lu, Blueprint Medicines

In this episode we speak with Ezgi Erdogan who is Oncology Market Access Director for Emerging Markets at GSK. In this discussion, we cover the unpredictability of emerging markets and the unique challenges this presents. Ezgi also shares her future predictions for access in emerging markets and talks about the importance of cross-functional collaboration in pharma to support the ever-changing landscape. The opinions shared in this podcast are Ezgi's own views.   

In this episode, we sit down with Pauline Payen, Director and Global Payer Strategy Lead for UCB’s Early Portfolio. Pauline shares her pragmatic insights into navigating the complexities of global market access.  Throughout her career, Pauline hasn't been shy of new opportunities, which has led to her taking on roles in commercial and marketing to expand her experience. In this discussion, we explore why market access is her passion. A field where, as she says, "What you do, can be life-changing for people."  Pauline describes the unique mindset essential for success in market access, as well as the importance of staying open to diverse opportunities along the way. It's an inspiring discussion on aligning personal values to professional growth. The opinions shared in this episode are Pauline's own views.

In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale. Rupert has been in pharma for over 27 years and is still going strong! In this discussion, he shares what resilience means to him and why he feels it's an important skill for market access leaders to leverage.Rupert shares some wonderful stories and advice that many of us can relate to and learn from. He also reveals what's keeping him passionate about access and value as he continues his career journey.  The views shared in this episode are Rupert's own opinions and not representative of the company he is working for. 

Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development. Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value.  The opinions shared in this episode are Korinna’s own views and not representative of the organisation she is working for. 

In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines.Ning shares her views on the complexities of market access and what makes the Biotech industry unique. She shares what inspired her to pursue a career in market access in biotechnology and why she feels it's a dynamic role and opportunity to 'connect the dots' with everything you learn.   Ning references and recommends the book "Science Business: The promise. The reality. And the future of biotech." By Gary Pisano. More information on this title is available here. https://amzn.eu/d/5nfsQVA  The opinions shared in this episode are Ning’s own views and not representative of the organisation she is working for.  

There’s no doubt that Market Access and Pricing leaders are fast becoming strategic partners in helping their wider organisations to understand the critical role of the function. In this episode, Marco Rauland from Merck KGaA joins us to explore this topic.Marco is Vice President Global Market Access and Pricing strategy, Pricing and Analytics. With over 25 years' experience in the field, he shares his views on the importance of clear communication when engaging all stakeholders and why MA&P leaders need to take a holistic approach to understanding all corners of drug development and launch. We also touch on the potential for AI in market access as the industry begins to explore the use cases of this latest innovation. Plus, the challenges market access leaders are facing and what strategies can help them overcome them.   The opinions shared in this episode are Marco’s own views and not representative of the organisation he is working for.  

In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it takes to be successful in market access, including why making mistakes are an opportunity for growth.   Yvonne explores why it's important to have strong foundations and understand the 'building blocks' of market access and shares great stories from the early stages of her career, which we're sure will resonate with many of the market access community.  

In this special episode which coincides with Disability Pride Month, we're joined by Senior Analyst Shubham Jadhav. Shubham has Becker Muscular Dystrophy (BMD) which is a form of muscular dystrophy and causes progressive muscle weakness.  Shubham is very passionate about raising awareness of rare diseases, disability, inclusivity and accessibility. He joins Keshav Nagaraja to share his story and what we can all be doing to help those with disabilities. It's an inspiring discussion which puts this very important topic in the spotlight. More information about Disability Pride Month can be found here: https://www.ameridisability.com/how-to-display-disability-pride/https://en.wikipedia.org/wiki/Disability_Pride_MonthFollow Shubham on LinkedIn here:  https://www.linkedin.com/in/shubham-jadhav-ms-%E2%99%BF-he-him-6235b5149/

Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing. Useful resources referenced in this podcast: March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022)https://www.canadianhealthpolicy.com/product/patented-medicines-expenditure-in-canada-1990-2022-8th-edition/January 2024 – Conference Board of Canada (Patented Medicines Expenditure in Canada 1990–2022 8TH Edition)https://www.conferenceboard.ca/wp-content/uploads/2022/10/access-and-time-to-patient_jan2024.pdfInnovative Medicines Canada – Access to Medicinehttps://innovativemedicines.ca/browse-by/access-to-medicine/April 2023 – Canadian Health Policy Journal (New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage)https://www.canadianhealthpolicy.com/wp-content/uploads/2022/01/SKINNER-APR-23-New-cancer-drugs-in-Canada-2012-to-2021-final-1.pdfApril 2022 – Canadian Health Policy Institute (Access to New Medicines in Canada 2016 – 2021)https://www.canadianhealthpolicy.com/posts/access-to-new-medicines-in-canada-2016-2021-federal-provincial-public-drug-programs-and-private-sector-drug-plans/The opinions shared in this podcast are Sam’s own views and not representative of the company he is working for. 

In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role. Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future of market access. The opinions shared in this episode are Joao's own views and not representative of the company he is working for.